Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference
September 13 2021 - 7:00AM
Enochian BioSciences, a company focused on gene-modified cellular
and immune therapies in infectious diseases and cancer, today
announced that it will be making a company presentation to
investors at the upcoming H.C. Wainwright Global Life Sciences
Conference.
Dr. Mark Dybul, CEO will provide an overview of
the company’s progress, including its innovative HIV, Hepatitis B,
influenza and coronavirus infections, and Oncology platforms. The
presentation will be available on-demand for conference attendees
beginning at 7:00 am Eastern on Monday September 13, 2021, and will
be available on the Enochian BioSciences website under the
Investors/Media section in Events and Presentations.
More information on the conference may be found
at H.C. Wainwright’s conference website.
About Enochian BioSciences, Inc. Enochian
BioSciences, Inc. is a biopharmaceutical company focused on
developing innovative platforms for gene-modified cellular and
immune therapies to potentially cure and treat deadly diseases. The
company’s gene-modified cell and immune therapy platforms can
potentially be applied to multiple indications, including HIV/AIDS,
Hepatitis B, all Corona and Influenza viruses, and Oncology. For
more information, please visit Enochianbio.com
Forward-Looking Statements Statements in this
press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties, including but not limited to the
success or efficacy of our pipeline. All statements other than
historical facts are forward-looking statements, which can be
identified by the use of forward-looking terminology such as
“believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or
similar expressions. Actual events or results may differ materially
from those projected in any of such statements due to various
uncertainties, including as set forth in Enochian BioSciences’ most
recent Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Enochian BioSciences undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Sep 2023 to Sep 2024